Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC Clears Caremark/AdvancePCS Deal, Expects Regional PBMs To Serve Small Employers

This article was originally published in The Pink Sheet Daily

Executive Summary

The merger’s completion awaits shareholder approval by both companies, which is expected to occur before the end of March. The combined firm is likely to have increased bargaining power that can be passed on to customers, FTC says.

You may also be interested in...

AmerisourceBergen Will Supply AdvancePCS Mail Pharmacy Six Months Past Merger Completion

AdvancePCS and ABC agree to extend their contract until Sept. 30; Caremark's acquisition of AdvancePCS is expected to close in March. ABC remains pessimistic about retaining the contract beyond September.

Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint

FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.

Risk Management Guidance Suggests Using Claims Data To Evaluate Safety Signals

Three FDA risk management final guidances recommend that sponsors collect a wide range of safety data during both the clinical trial and postmarketing periods of drug development. The agency suggests that sponsors hold discussions with FDA before settling on drug study designs or postmarketing activities.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts